Reece C Budinich
Overview
Explore the profile of Reece C Budinich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levinstein M, Budinich R, Bonaventura J, Schatzberg A, Zarate Jr C, Michaelides M
Am J Psychiatry
. 2025 Jan;
182(3):247-258.
PMID: 39810555
Ketamine is a racemic compound and medication comprised of ()-ketamine and ()-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug....
2.
Levinstein M, De Oliveira P, Casajuana-Martin N, Quiroz C, Budinich R, Rais R, et al.
Mol Psychiatry
. 2024 Dec;
PMID: 39639176
No abstract available.
3.
Di Ianni T, Ewbank S, Levinstein M, Azadian M, Budinich R, Michaelides M, et al.
Nat Commun
. 2024 Jan;
15(1):893.
PMID: 38291050
Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture...
4.
Levinstein M, De Oliveira P, Casajuana-Martin N, Quiroz C, Budinich R, Rais R, et al.
Mol Psychiatry
. 2023 Dec;
29(3):624-632.
PMID: 38145984
(R,S)-methadone ((R,S)-MTD) is a µ-opioid receptor (MOR) agonist comprised of (R)-MTD and (S)-MTD enantiomers. (S)-MTD is being developed as an antidepressant and is considered an N-methyl-D-aspartate receptor (NMDAR) antagonist. We...
5.
Levinstein M, Carlton M, Di Ianni T, Ventriglia E, Rizzo A, Gomez J, et al.
Biol Psychiatry
. 2023 Feb;
93(12):1118-1126.
PMID: 36841701
Background: (S)-ketamine is an NMDA receptor antagonist, but it also binds to and activates mu opioid receptors (MORs) and kappa opioid receptors in vitro. However, the extent to which these...
6.
Levinstein M, Ventriglia E, Gomez J, Budinich R, Marton J, Henriksen G, et al.
Mol Imaging Biol
. 2022 Aug;
25(2):384-390.
PMID: 35999424
Purpose: 6-O-(2-[F]Fluoroethyl)-6-O-desmethyl-diprenorphine ([F]FE-DPN) is regarded as a non-selective opioid receptor radiotracer. Procedure: Here, we report the first characterization of [F]FE-DPN synthesized from the novel precursor, 6-O-(2-tosyloxyethoxy)-6-O-desmethyl-3-O-trityl-diprenorphine (TE-TDDPN), using a one-pot,...